Amylin Exenatide NDA Filing Expected Mid-2004; Symlin Launch in Q1
Executive Summary
Amylin is eyeing a mid-2004 filing date for its exenatide NDA
You may also be interested in...
Lilly/Amylin Submit Exenatide For Diabetes; Could Be Insulin Alternative
Lilly is positioning the pending type 2 diabetes therapy exenatide for patients on oral agents who might normally be given insulin
Lilly/Amylin Submit Exenatide For Diabetes; Could Be Insulin Alternative
Lilly is positioning the pending type 2 diabetes therapy exenatide for patients on oral agents who might normally be given insulin
Symlin “Approvable” Letter Will Be Addressed By Ongoing Trials, Amylin Says
Amylin hopes that data from two ongoing open-label Symlin trials will address questions outlined by FDA in an "approvable" letter for the diabetes agent